We are live on ! Find out more
JRJ

Jeffrey R. Jay Portfolio holdings

AUM $127M
This Fund
S&P 500
This Quarter Est. Return
+8.05%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$127M
AUM Growth
–
Cap. Flow
+$118M
Cap. Flow %
93.5%
Top 10 Hldgs %
72.25%
Holding
32
New
31
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$21.1M
2
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$17.3M
3
STML
Stemline Therapeutics, Inc.
STML
+$9.48M
4
AMBI
Ambit Biosciences Corp
AMBI
+$7.15M
5
FLNA
Filana Therapeutics
FLNA
+$7.01M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 48.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HPTX
1
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$21.2M 16.76%
+963,961
New +$21.1M
FURX
2
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$16.8M 13.3%
+494,100
New +$17.3M
STML
3
DELISTED
Stemline Therapeutics, Inc.
STML
$14.2M 11.22%
+595,493
New +$9.48M
ALBO
4
DELISTED
Albireo Pharma Inc
ALBO
$7.75M 6.12%
+61,795
New +$6.43M
AMBI
5
DELISTED
Ambit Biosciences Corp
AMBI
$7M 5.53%
+1,000,000
New +$7.15M
GERN icon
6
Geron
GERN
$924M
$5.63M 4.45%
+3,967,500
New +$4.31M
FLNA
7
Filana Therapeutics
FLNA
$51.2M
$5.13M 4.06%
+331,824
New +$7.01M
NUWE icon
8
Nuwellis
NUWE
$263K
– –
0
– –
DRTX
9
DELISTED
DURATA THERAPEUTICS INC COM STK (DE)
DRTX
$4.6M 3.64%
+639,433
New +$4.69M
NDZ
10
DELISTED
NORDION INC COM STK (CDA)
NDZ
$3.98M 3.14%
+537,500
New +$3.89M
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$3.93M 3.1%
+1,596,720
New +$3.83M
ACHV icon
12
Achieve Life Sciences
ACHV
$644M
$3.4M 2.69%
+158
New +$3.53M
IPXL
13
PUT
DELISTED
Impax Laboratories, Inc.
IPXL
$2.99M 2.36%
+150,000
New +$2.66M
TRIB
14
Trinity Biotech
TRIB
$6.79M
$2.75M 2.17%
+32,628
New +$2.71M
SRGA
15
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$2.53M 2%
+22,463
New +$2.75M
DYAX
16
DELISTED
DYAX CORPORATION
DYAX
$2.52M 1.99%
+728,063
New +$2.38M
SVRA icon
17
Savara
SVRA
$1.13B
$2.49M 1.97%
+82,857
New +$3.68M
PLX icon
18
Protalix BioTherapeutics
PLX
$192M
$1.96M 1.55%
+39,901
New +$2.12M
MYGN icon
19
PUT
Myriad Genetics
MYGN
$584M
$1.88M 1.49%
+70,000
New +$2.03M
VOLC
20
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$1.81M 1.43%
+100,000
New +$1.91M
GYRE icon
21
Gyre Therapeutics
GYRE
$675M
$1.57M 1.24%
+467
New +$1.78M
AVNR
22
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$1.19M 0.94%
+258,600
New +$889K
XNPT
23
DELISTED
XENOPORT, INC.
XNPT
$1.15M 0.91%
+232,977
New +$1.41M
LITS
24
Lite Strategy Inc
LITS
$33.6M
$1.12M 0.89%
+7,883
New +$1.31M
PTX
25
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$1.07M 0.85%
+29,719
New +$1.11M
1
2

Similar funds

CCM
Cazenove Capital Management London, United Kingdom $125M AUM
TP
Traxis Partners Greenwich, Connecticut $129M AUM
TBI
Telemus Beacon Investment Ann Arbor, Michigan $94.1M AUM
RRWJ
R. Robert Woodburn Jr $93.1M AUM
MIA
Mainstream Investment Advisers New Albany, Indiana $163M AUM
FLC
Francis L. Coolidge $82.2M AUM
HSA
Holt-Smith Advisors Madison, Wisconsin $70.9M AUM
NM
NBGE Manager Waltham, Massachusetts $65.2M AUM

Jeffrey R. Jay's Q2 2013 Portfolio in Review

Q2 2013 is the first quarter with a 13F filing on record for Jeffrey R. Jay, which disclosed 32 positions worth $127M. Its ten largest holdings account for 72% of the portfolio.

Its largest position is HYPERION THERAPEUTICS INC COM STK (DE): 963,961 shares worth $21.2M.

By sector, the portfolio is most concentrated in Healthcare at 48% of assets.

  • Jeffrey R. Jay's largest Q2 2013 buy was HYPERION THERAPEUTICS INC COM STK (DE): 963,961 shares worth $21.2M.
  • Jeffrey R. Jay's ten largest holdings make up 72% of its $127M portfolio in Q2 2013.
  • Jeffrey R. Jay disclosed 32 positions in Q2 2013, its first 13F filing on record.

Based on Jeffrey R. Jay's 13F filing for Q2 2013, filed 14 Aug 2013.